For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Rezum Treatment | Participants underwent the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia. They were followed for 5 years for adverse events and quality of life data. Rezum System: The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate "wet" thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure. | 2 | None | 3 | 15 | 14 | 15 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Subject was surgically treated for a pre-existing hernia. | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Adenocarcinoma | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Urinary Retention | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Urinary Retention | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Dysuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Poor Stream | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Urinary Urgency | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Infection (non UTI) | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Other | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Terminal Dribbling | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Urinary Frequency | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Prostatic Urethral Injury | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Ureteral Calculi | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Hematuria with Clots and Retention | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| UTI - Prophylaxis | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Urinary Incontinence - Urge | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Fever | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Urinary Tract Infection (UTI) - Suspected | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Hematuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |